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Abstract
A novel method for the fabrication of polymeric particles on the order of tens of nanometers to several
microns is described. This imprint lithographic technique called PRINT™ (Particle Replication In
Non-wetting Templates), takes advantage of the unique properties of elastomeric molds comprised
of a low surface energy perfluoropolyether network, allowing the production of monodisperse, shape-
specific nanoparticles from an extensive array of organic precursors. This engineered nature of
particle production has a number of advantages over the construction of traditional nanoparticles
such as liposomes, dendrimers, and colloidal precipitates. The gentle “top down” approach of PRINT
enables the simultaneous and independent control over particle size and shape, composition, and
surface functionality, and permits the loading of delicate cargos such as small organic therapeutics
and biological macromolecules. Thus, this single tool serves as a comprehensive platform for the
rational design and investigation of new nanocarriers in medicine, having applications ranging from
therapeutics to advanced diagnostics. Preliminary in vitro and in vivo studies were conducted,
demonstrating the future utility of PRINT particles as delivery vectors in nanomedicine.
Monodisperse 200 nm poly(ethylene glycol)-based (PEG) particles were fabricated using PRINT
methodology and characterized via scanning electron microscopy and dynamic light scattering.
Incubation with HeLa cells showed very little cytotoxicity, even at high concentrations. The
biodistribution and pharmacokinetics of [125I]-labeled particles were studied in healthy mice
following bolus tail vein administration. The particles were distributed mainly to the liver and the
spleen with an apparent distribution t1/2 of approximately 17 min followed by slow redistribution
with a t1/2 of 3.3 h. The volume of distribution for the central and peripheral compartments was found
to be approximately 3 mL and 5 mL, respectively.
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Despite continued progress in the identification, characterization, and synthesis of advanced
therapeutics, the full potential of such innovations can only be achieved with the concomitant
realization of in vivo profiles ideal for pharmacological intervention. In the realm of drug
discovery, the hindrance to obtaining such a profile may be as simple as poor solubility in
biological media. For instance, it has been reported that ten percent of marketed drugs suffer
from solubility problems, over a third of pipeline drugs are poorly soluble, and almost two-
thirds of drugs coming from early pre-clinical development have low solubility [1]. As such,
almost forty percent of all possible drug targets fail early due to poor solubility characteristics.
More complex problems with drug candidates may include unfavorable pharmacokinetics, and
high systemic toxicity. Particular attention must also be given when considering the delivery
of biochemically labile substances such as siRNA and other oligonucleotides for gene therapy,
as these sensitive cargos need to be protected during circulation. In addition, they need to be
delivered to the appropriate tissue or organ, and released intracellularly into the cytosol or
nucleus to be effectively used as therapeutics. Finally, the efficient delivery of detection and
imaging agents is an extremely important step in the early diagnosis and treatment of disease.
The development and utilization of nanocarriers in response to many of the aforementioned
problems encountered in vivo has led to dramatic improvements in the biological profile of
important therapies. Intense research in drug delivery over the past few decades has seen the
design and construction of valuable nanocarriers such as liposomes, micelles, dendrimers,
polymer particles, and colloidal precipitates [2-9]. However, only a handful of drugs and
imaging agents delivered using these classical approaches have made it into the clinic [1,8].
One underlying reason for the delayed development is that none of these approaches offers the
ability to comprehensively, simultaneously, and independently address several different design
criteria. The ability to meet such demanding parameters is quintessential to the design of
effective delivery vectors and has been the focus of intense research in our laboratory. Herein,
we report the utilization of recent breakthroughs in the nanofabrication of polymeric particles
to develop an effective platform delivery system for use in nanomedicine.
Our technique, called PRINT (Particle Replication In Non-wetting Templates), is based on
the exploitation of the low surface energy of novel fluoropolymeric molds (Fig. 1) [10-12].
The molds are derived from liquid perfluoropolyether (PFPE) precursors, which can be
photochemically crosslinked at room temperature. The resulting elastomeric solids enable
high-resolution imprint lithography, an emerging technique from the microelectronics
industry, to fabricate a variety of organic particles. PRINT is therefore an adaptation of the
highly precise mass production technologies used today for the fabrication of nanoscale,
silicon-based devices found in the microelectronics field. By developing lithographic
technologies that are able to fabricate transistors that are smaller and smaller, companies have
been able to increase the number of transistors on a microprocessor to over one billion: this
represents an increase of over six orders of magnitude since the early 1970’s [13,14]. The
minimum feature size currently found on each individual transistor is under 100 nm
(approximately the size of an individual virus particle) [15,16]. The state-of-the-art in the
microelectronics industry has finally reached the size scale appropriate for the ideal drug
delivery vector. It is now timely to envision and propose the use of lithographic techniques
found in the microelectronics industry to fabricate carriers of precise size for use in
nanomedicine. Indeed, transistors in today’s microelectronic devices are even smaller than
traditional drug delivery carriers that have been studied over the last 25 years: micelles,
liposomes, and polymer particles.
The nature of PRINT technology takes drug delivery for the first time into the uncharted realm
of engineered drug therapies given its á la carte approach and versatility. This innovative tool
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allows for the simultaneous control over all of the parameters that are essential in the rational
design of conventional delivery vectors in nanomedicine. PRINT allows for the precise control
over particle size (20 nm to >100 μm) through use of an appropriately designed master template.
The advanced imprint lithography of PRINT ensures replication of the identical master features
to afford particles that are truly monodisperse. Particle shape is also controlled through the
judicious choice of a master, and geometries such as spheres, cylinders, discs, and toroids with
defined aspect ratios can be accommodated. The composition of particles made using PRINT
is also readily tunable and amendable to the inclusion of a variety of organic matrices including
albumin, hydrogels, PLLA, PLGA, etc. (Fig. 2). Moreover, the porosity, texture, and modulus
of the particles can be altered in a logical fashion through careful alteration of the matrix
formulation. In view of the fact that PRINT is compatible with a wide range of chemistries and
the gentle nature in which particles are fabricated, this technology enjoys the straightforward
incorporation of a variety of cargos. The inclusion of hydrophilic or hydrophobic therapeutic
molecules, biologicals, peptides, proteins, oligonucleotides, siRNA, contrast agents,
radiotracers, and fluorophores can be accommodated through inclusion in the particle matrix.
The concentration of such cargos in the particles can be exactly chosen to meet specific needs
and standards since PRINT does not rely on the kinetic trapping of external molecules during
particle fabrication as is the case with liposomes and micelles. Finally, particle surface
properties are readily modified though either the matrix composition or post-functionalization
with surface moieties. Thus, particle surfaces are amenable to decoration with targeting
peptides, antibodies, aptamers, avidin/biotin complexes, cationic/anionic charges, and
“stealth” poly(ethylene glycol) (PEG) chains for steric stabilization. We believe that PRINT
is the only technology that can independently design in these attributes to create truly
engineered nanovectors for drug therapies. For the first time, key therapeutic parameters such
as bioavailability, biodistribution, and target-specific cell penetration can be simultaneously
designed into a therapy. In this report we document the first in vivo study of PRINT particles
administered intravenously into healthy mice. The promising biodistribution profile and blood
pharmacokinetics of 200 nm non-targeted radiolabeled PEG-based nanogels fabricated using
PRINT methodology are discussed.
2. Materials and Methods
2.1 Materials
Fluorocur™, the perfluoropolyether used as the molding material in the PRINT process, was
purchased from Liquidia Technologies (Product # 2M-140). Trimethylolpropane ethoxylate
triacrylate (Mn = 428 g/mol) (Aldrich), was passed through a short plug of alumina prior to
use to remove inhibitor. Poly(ethylene glycol) monomethyl ether monomethacrylate (Mn =
1,000 g/mol) (Polysciences), para-hydroxystyrene (Alfa Aesar, 10% (w/w) in propylene
glycol) and 2,2-diethoxyacetophenone (Aldrich) were used as received without further
purification. Iodogen® pre-coated tubes were purchased from Pierce Biotechnology, Inc., and
radioactive iodine (Na125I) was purchased from Perkin Elmer Life and Analytical Sciences,
Inc. as 100 mCi/mL in 10-5 M NaOH. HeLa cells and all cell culture media (MEM, OptiMEM)
were purchased from the tissue culture facility at The University of North Carolina at Chapel
Hill. CellTiter 96* AQueous One Solution Cell Proliferation Assay (MTS) was purchased from
Promega Corporation. The lysis agent used for negative controls in in vitro viability studies
with HeLa cells was 9% w/v solution of Triton® X-100 in water. Silicon templates used as
masters were obtained from Benchmark Technologies. C57BL/6J mice were purchased from
The Jackson Laboratory. Ketamine HCl (100 mg/mL) was purchased from Abbott
Laboratories. Cholesterol and 1,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC) were
purchased from Avanti Polar Lipids, Incorporated. All animal experiments were conducted in
accordance with guidelines set forth by The University of North Carolina at Chapel Hill, and
approval was obtained for the completion of these experiments.
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2.2 Preparation of PRINT nanoparticles
The fabrication of patterned Fluorocur™ molds has been described elsewhere [10]. Briefly,
20 mL of Fluorocur™ resin containing 0.1% (w/w) of 2,2-diethoxyacetophenone was pooled
in the center of an 8 inch patterned master (with feature sizes of 200 nm) which was set up
inside an enclosed UV chamber. Ten minutes was allowed to pass so that the Fluorocur™ resin
was spread out over the entire 8 inch wafer. The entire system was then purged with nitrogen
for 3 minutes. Following this, the coated wafer was exposed to UV irradiation (λ = 365 nm,
power > 20 mW/cm2) for 2 minutes to cure the Fluorocur™ resin. The elastomeric mold was
then removed from the master template by gently peeling it away from the silicon surface.
In these experiments, the PRINT particles were derived from a mixture composed of 78% (w/
w) PEG triacrylate, 20% (w/w) PEG monomethyl ether monomethacrylate, 1% (w/w) 2,2-
diethoxyacetophenone, and 1% (w/w) para-hydroxystyrene. A 10% (w/v) solution of this
mixture in 2-propanol (filtered through a 0.22 μm PTFE filter) was prepared. This solution (1
mL) was then sprayed onto a Fluorocur™ patterned mold using an air brush and residual 2-
propanol was allowed to evaporate over 10 minutes. A poly(ethylene) sheet (American Plastics
Co.) was then placed over the 8 inch (diameter) mold ensuring that the entire active area was
covered. This poly(ethylene) sheet was then peeled back at a rate of approximately 2.5 cm/
min. Following this, the mold was placed in a UV curing chamber. The chamber was purged
with nitrogen for 3 minutes and UV irradiation was applied (λ = 365 nm, power > 20 mW/
cm2) for 2 minutes.
To facilitate removal of the particles from the mold, a physical means for harvesting the
particles was utilized. Specifically, a 2 mL aliquot of acetone (filtered through a 0.22 μm PTFE
filter) was placed on the particle-filled mold and this drop of acetone was gently moved along
the surface of the mold using a glass slide. The movement of the glass slide facilitated release
of the particles from the mold. The suspended particles were collected in a 50 mL Falcon tube
and diluted to the 50 mL mark with filtered acetone after particle collection was complete. The
suspension was vortexed for 10 minutes and was centrifuged at 3200 rpm for 30 minutes using
a IEC CENTRA CL2 Centrifuge (Thermo Electron Corporation). The supernatant was
removed via aspiration and the particle pellet was redispersed in 50 mL of fresh acetone by
vortexing for 10 minutes followed by centrifugation for an additional 30 minutes. This process
was repeated once more and after aspiration the particles were redispersed in 5 mL of distilled
water by sonicating the dispersion for 15 minutes. The particle dispersion was filtered through
a 20 μm filter into a fresh 50 mL Falcon tube, and diluted to the 50 mL mark with acetone.
This particle suspension was then centrifuged for one hour. The supernatant was removed via
aspiration and the particle pellet was redispersed in 50 mL of fresh acetone by vortexing for
10 minutes followed by centrifugation for an additional 30 minutes. This washing process was
repeated once more (with acetone) and after aspiration the particles were redispersed in a
minimal amount of acetone, transferred to a tarred Eppendorf tube, and centrifuged in a
microfuge (Fisher Scientific) for 20 minutes. The supernatant was removed and the pellet was
dried in a vacuum oven overnight, massed, and dispersed in the appropriate amount of sterile
water to make a 10 mg/mL dispersion of particles.
2.3 Preparation of liposomes
Lipids (DSPC:Cholesterol, 55:45 mol) were dissolved in chloroform and evaporated to dryness
in a rotary evaporator under reduced pressure at 50 °C. After leaving the lipid film overnight
under reduced pressure, the film was hydrated with PBS at pH 7.0. Unilamellar liposomes were
formed by extrusion with 20 passes through a double-stacked polycarbonate membrane
(Whatman Nucleopore) with a pore size of 200 nm, resulting in a liposome diameter of 177
nm with a polydispersity of 0.026 as determined by dynamic light scattering [17,18].
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2.4 Particle size analysis of PRINT nanoparticles using scanning electron microscopy (in the
dry state)
The size of PRINT nanoparticles was analyzed via scanning electron microscopy (Hitachi
model S-4700). Particle dispersions were prepared at concentrations of 0.5 mg/mL, and a drop
of this solution was placed on a glass slide. The drop was then allowed to dry, and the glass
slide was coated with 1.5 nm of Pd/Au alloy using a Cressington 108 auto sputter coater
(Cressington Scientific Instruments Ltd.). The Pd/Au coated glass slide was then adhered to
the sample holder using double-sided adhesive tape, and placed inside the vacuum chamber of
the SEM and observed under low vacuum (10-6 Torr).
2.5 Particle size analysis of PRINT nanoparticles, and liposomes, using dynamic light
scattering (in suspension)
The size and polydispersity of PRINT nanoparticles was analyzed via dynamic light scattering
(DLS) using a 90Plus Particle Size Analyzer (Brookhaven Instruments Corporation). The
particles were dispersed in PBS at a concentration of 0.5 mg/mL and measured without
filtration at 25 °C and 37 °C. The DSPC:CHOL liposomes were diluted with PBS to a
concentration of 0.5 mg/mL, and were measured under the same conditions as PRINT particles.
2.6 Zeta potential measurements
The zeta potential of PRINT nanoparticles was measured using a ZetaPlus Zeta Potential
Analyzer (Brookhaven Instruments Corporation). The nanoparticles were dispersed in water
at a concentration of 0.3 mg/mL and the zeta potential was measured.
2.7 Radiolabeling of PRINT nanoparticles with 125I
PRINT nanoparticles were radiolabeled using Iodogen™ solid phase oxidant in the presense
of Na125I. Briefly, 10 mg of PRINT particles in 1 mL of H2O, 53 μL of phosphate buffered
saline, and 1 mCi of Na125I in 10 μL of 10-5 M NaOH were added to an Iodogen™ pre-coated
tube (50 μg of Iodogen™ reagent) and the tube was swirled every other minute for 15 minutes.
The radiolabeled particle solution was then transferred to a pre-weighed 1.5 mL Eppendorf
tube. The original reaction tube was rinsed with one 20 μL portion of 1 mM KI and with two
100 μL portions of water and the rinsing solutions were added to the tube containing
radiolabeled particles followed by the addition of NaHSO3 (1 μmol/10 μL). The particle
dispersion was then centrifuged for 10 minutes at 15,000 × g using an Eppendorf centrifuge
5415 D (Eppendorf). The supernatant was removed and the particles were washed with four
500 μL portions of water (until the radiation in the supernatant was no greater than the
background, ensuring complete removal of non-specifically bound 125I) and evaporated to
dryness in a SpeedVac SC100 (Savant Instruments). The total mass recovered was 9.45 mg.
The specific activity was measured with a Beckman Gamma 5500B gamma counter
(Laboratory Technologies) and found to be 5.5 μCi/mg PRINT particles.
2.8 In vitro cytotoxicity
HeLa cells were seeded in 100 μL of media [Minimum Essential Medium (MEM) containing
Earle’s salts and supplemented with 1 mM sodium pyruvate and non-essential amino acids] at
a density of 5 × 103 cells per cm2 into a 96-well microtitre plate. Cells were allowed to adhere
for 24 h before MEM was replaced with Opti-MEM (90 μL per well) and the particle
preparation (10 μL per well in PBS). Positive controls contained PBS alone. HeLa cells were
incubated with the PRINT particles for 4 h at 37 °C in a humidified 5% CO2 atmosphere. After
the 4 h incubation period, negative controls were prepared by the addition of 2 μL of lysis
solution to a few wells containing cells only. After 2 minutes, the MTS assay solution was
added (20 μL per well) into each well. The cells were then incubated for an additional 1 h at
37 °C in a humidified 5% CO2 atmosphere. The optical density at 450 nm was measured using
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a BioRad Model 3550 microplate reader (BioRad Laboratories). The viability of the cells
exposed to neutral PRINT particles was expressed as a percentage of the viability of cells grown
in the absence of particles.
2.9 Biodistribution of [125I]-labeled PRINT particles
C57Bl/6J mice were housed under specific pathogen-free conditions for one week and were
used at 8 weeks of age (~18 g). Animals were injected intravenously via bolus tail vein
administration with 0.32 mg of [125I]-labeled PRINT particles with a specific activity of 4.3
μCi/mg in 100 μL of PBS (phosphate buffered saline, Sigma-Aldrich). At 10 min, 30 min, 1,
3, and 8 h after dosing, groups of four mice were anesthetized by intraperitoneal injection of
100 μL of ketamine HCl solution in PBS (50 mg/mL). Blood was collected via cardiac puncture.
Samples of blood and organs harvested (liver, kidneys, spleen, lungs, and heart) were weighed
and counted to determine the total radioactivity in a Beckman Gamma 5500B gamma counter
(Laboratory Technologies). An additional four animals were kept in a metabolic cage after
injection of the [125I]-labeled PRINT nanoparticles. At 24 h post-injection, the accumulated
urine and feces were collected for radioactivity measurements. After these animals were
sacrificed (as described above) the blood as well as the organs were removed, weighed, and
assayed for radioactivity.
3. Results and Discussion
3.1 The Print Process
In the PRINT process (Fig. 1), the permanent silicon master template is fabricated using
advanced lithographic techniques. The liquid PFPE fluoropolymer is then added to the surface
of the master template. A positive spreading coefficient allows the perfluoropolyether to wet
the nanoscale features of the master template with extremely high fidelity. After the
fluoropolymer has wet the master template it is photochemically cross-linked and peeled away
to generate a precise mold having nanoscale cavities. The low surface energy and high gas
permeability of the PRINT mold enables the organic liquid precursor to the drug carrier
particles to fill the cavities through capillary action, but it does not form an inter-connecting
“flash” layer of liquid wetting the land area between the cavities. Such specific wetting and
filling enables the fabrication of freestanding and harvestable particles that have the same
precise shape of the silicon master template from which they were derived. Once the liquid in
the mold cavities is converted to a solid using a wide range of gentle chemistries, the array of
organic particles can be removed from the mold either by physical methods or by bringing the
mold in contact with an adhesive layer (e.g. surgical adhesive/water soluble excipient layer).
Physical methods were used herein to harvest the PRINT particles, which were then purified,
characterized, and radiolabeled for biodistribution studies.
3.2 Characterization of PRINT Nanoparticles
The particle composition was engineered to produce biologically relevant delivery vectors.
Several monomers were added to introduce specific functionality into the hydrogel
nanoparticles: poly(ethylene glycol) triacrylate, poly(ethylene glycol) monomethyl ether
monomethacrylate, and p-hydroxystyrene (PHS) (Fig. 3). Poly(ethylene glycol) derivatives
have long been known to impart biocompatibility, solubility, stability, and increased circulation
times to proteins, liposomes, and particles [19-23]. The phenol-containing monomer, PHS,
was selected as a chemical handle so that gentle radioiodination of the particles was possible.
Since mPEG1000 monomethacrylate is a solid, 2-propanol was used to obtain a homogeneous
solution of the monomer precursors, so that a thin film of monomer mixture could be sprayed
onto the PFPE mold. To this point, any solvent (or combinations of solvents) can be used in
the PRINTing process, as long as the contact angle of the resultant solution onto the PFPE
mold is less than 90°. Alternatives to this method include a melt PRINT process, where the
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monomers are heated to above their melting point, and the PRINT process is carried out,
allowing a solvent-free process.
The uniformity of size and shape of the hydrogels was confirmed using scanning electron
microscopy (SEM, Fig. 4). The micrographs show the isolation of thousands of virtually
identical cylindrical particles, thus verifying PRINT’s ability to copy the nanoscale features of
a patterned wafer with high precision. The diameter of the particles in the dry state was
determined from the scanning electron micrographs to be 201 ± 10 nm and the height was
determined to be 155 ± 10 nm. A dry sample is required for SEM and thus the micrographs
obtained do not represent the dispersion the particles have once in solution.
The nanocarriers used most frequently today for the delivery of therapeutics in the clinic can
best be classified under the general heading of self-assembled structures. Nanovectors fitting
this description include micelles, liposomes, and protein aggregates. As a result of their inherent
dynamic nature, these nanoparticles derived from the self-assembly of small molecules would
be expected to undergo structural changes once in vivo. As such, it is difficult to make a direct
connection between the particle formulation prior to administration and the therapeutic
outcome. As an example of this behavior, the size and polydispersity of liposomes and PRINT
particles in water were investigated via dynamic light scattering at room temperature (25 °C)
and then at physiological temperature (37 °C) over the course of several hours (Fig. 5). At 25
°C both liposomes and PRINT particles have a low polydispersity immediately upon formation
or dispersion. Upon heating to 37 °C, the mean diameter and polydispersity of liposomes
changes dramatically as a function of time. Over the time course of 6 h at physiological
temperature, the PRINT particles remain stable as observed by a steady size and polydispersity
(234 ± 12 nm, PDI = 0.005). This could be an important attribute in the design of nanocarriers,
since it is expected that the size and polydispersity of dynamic structures may change even
more rapidly once in the serum. The zeta potential of these PRINT nanoparticles was measured
to be-30.4 ± 1.5 mV.
3.3 Cytotoxicity studies in vitro
The cytotoxicity of the PRINT nanoparticles was assessed in a cursory manner using a MTS
cell viability assay [24]. This particular assay is a colorimetric evaluation that determines the
number of living cells by quantifying the amount of formazan product present, which is directly
proportional to the number of viable cells. Figure 6 shows high viability relative to the negative
control, supporting the non-toxic nature of the nanoparticles, even at high concentrations (100
μg/mL is equivalent to 800,000 particles/cell). Based on the toxicity data obtained, the PRINT
nanoparticles appear biocompatible and suitable for future in vivo studies.
3.4 In vivo biodistribution studies of PRINT particles in healthy mice
In this study, 200 nm [125I]-labelled PRINT particles were administered into healthy C57BL/
6J mice via tail vein bolus injection at a dose of 20 mg/kg. The particles were radiolabeled
using Iodogen® following the procedure recommended by the supplier (Pierce). The tissue
distribution was monitored using a gamma counter, and the percent recovery of injected dose
was calculated from the measured radioactivity. Figure 7 shows the tissue distribution of 200
nm PRINT nanoparticles at 10 min, 30 min, 1 h, 3 h, 8 h, and 24 h post-injection. Throughout
the time-course of the study, the 200 nm PRINT particles were distributed mainly in the liver
and spleen. The total recovery from these two organs amount to as much as 30% over the 24
h study period. This observation is consistent with the fact that the sinusoidal walls of these
organs are lined with discontinuous endothelium that allows for passive entrapment of foreign
particulates [25,26]. Although the present study does not provide any direct evidence for or
against it, it is likely that these particles are eventually taken up by the resident macrophages
possibly subsequent to opsonization with serum proteins [27].
Gratton et al. Page 7













The particle accumulation was not significant in other organs harvested, often ~ 1% of the
injected dose was found in the kidneys, heart, and lungs. The extent of particle accumulation
reported in these organs may slightly over-represent the actual accumulation since the organs
were not thoroughly rinsed to remove residual blood. Tails were collected in an effort to
monitor the amount of nanoparticles that were retained at the injection site. A significant
amount of injected particles were found in the tail, especially during the initial 3 h period. This
may be due to the rupture of blood vessels upon rapid injection of a large number of fine
particles in a short period of time (< 5 seconds), creating endothelial gaps for particle retention.
Finally, a trace but significant amount of radioactivity was observed in thyroid gland, possibly
indicating the biodegradation of particles, yielding radioactive I2. Production of iodine from
biochemical degradation of iodinated proteins or peptides is not uncommon and is also
consistent with the observation that total recovery decreased steadily over the 24 h period
studied (vide infra) [28].
Total recovery of the radioiodinated particles was found to decrease with time, beginning with
an 81 ± 6 % recovery at 10 minutes post-injection and ending with a 24 ± 7 % recovery after
24 h (data not shown). Here, the total recovery was calculated from radioactivity measured
only from the blood, liver, kidneys, spleen, lungs, heart, tail, bone marrow, and thyroid. In an
effort to achieve a full mass balance, four mice were kept in metabolic cages for 24 h so that
urine and feces could be collected and analyzed. For these mice, additional tissues and body
parts such as fat, muscle, head, legs, intestines, and the remainder of the body were also
analyzed for additional radioactivity. It was found that with these additional measurements,
the total recovery at 24 h post-injection improved from 24 ± 7 %, with the main organs only,
to 58 ± 4 %. The appearance of radioactivity in the thyroid gland throughout the study period
(approximately 1% of injected dose) and in urine 24 h after dosing (as much as 8.6%) may
suggest particle degradation [29]. This is also consistent with a hypothesis that loss of volatile
radioactive iodine via the lungs could have contributed to the time-dependent decrease in total
recovery of radioactivity observed.
As shown in Figure 8, the disappearance of PRINT particles from circulation was bi-
exponential. The data set was fitted to a two-compartmental pharmacokinetic model with
reversible distribution between central and peripheral compartments and with elimination from
the central compartment. The pharmacokinetic parameters obtained using WinNonLin 5.0.1
(Pharsight Corporation) show the initial phase of rapid distribution with an apparent t1/2 of 17
min. The rapid distribution is not surprising considering that the steric coat on the PRINT
particles is only a low molecular weight PEG chain (9 mol %, 20% w/w of 1-kDa PEG
monomethyl ether). It has been suggested that the optimal coating for the creation of long-
circulating liposomes is 3-7 mol % of 2-5 kDa PEG [30]. The shorter PEG chains used in the
current particle formulation may not offer a radius of protection that is sufficient to effectively
block the adsorption of opsonic proteins. The subtle nuances that both the degree of PEG
incorporation and the molecular weight of PEG play in prolonging the circulatory t1/2 are well
documented for other types of nanocarriers [30-32].
Volumes of distribution of central and peripheral compartments were found to be 3 and 5 mL,
respectively. Considering the blood volume of approximately 1.7 mL/20 g mouse, liver of 0.8
g, and spleen < 0.1 g, these values appear to be somewhat exaggerated, however, they certainly
rule out any significant extravasation. Since the stability of the radiolabel is not well established
in the present study and since it is the radioactivity that is monitored, it is difficult to
unambiguously interpret the slow phase of radioactivity decay in the later time-points with an
apparent t1/2 of 3.3 h. The appearance of radioactivity in urine strongly suggests that these
PRINT particles and/or their degradation products must be cleared rapidly from the blood.
Thus, the slow elimination phase may well represent slow re-distribution of particles or particle
remnants between the blood and organs/tissues.
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The AUC, a measure of total availability of particles in the circulation for organ distribution
extrapolated to infinite time, was determined to be 191 μg·h/mL. Unmodified, conventional
liposomes show dose-dependent pharmacokinetic parameters, including AUC upon i.v.
administration. A liposome dose equivalent to the dose in the present study, 20 mg/kg, shows
AUC values of approximately 70 to 700 μg·h/mL. Thus, the present data are certainly in
agreement with that reported for liposomes [33].
Conclusions
This paper is concerned with the characterization of nanofabricated particles that are
monodisperse in size and shape. It includes the first pharmacokinetic evaluation of PRINT-
derived cylinders of 200 nm. PRINT allows for powerful realizations regarding
pharmacokinetics of nanoparticles since intersubject variation can be ascribed fully to the
subject and not to variations of the nanocarrier. This is a significant step in pharmacokinetic
analysis since it eliminates the effect that polydisperse samples can have on biodistribution.
This in turn allows us to be able to precisely demonstrate the effect of size, composition, the
addition of cargo, modulus, and functionalization on biodistribution, which has never been
possible until now. Current efforts are focused on the creation of long-circulating PRINT
particles for the eventual use in engineered drug therapies. Results will be reported in due
course.
PRINT is the first general, singular method capable of forming organic nanoparticles in which
critical design parameters can be precisely and independently tailored bringing a greater
understanding of cause-and-effect to the field of nanomedicine. With the unprecedented ability
of PRINT technology to control particle size, shape, composition, modulus, cargo, and surface
properties, questions such as “what interrelated role does shape, size and mechano-chemico
functionality play on the biodistribution of carriers in vivo?” and, “how can this understanding
translate into more efficacious detection, diagnosis, therapeutic and prevention strategies?”
can finally begin to be answered. As such, PRINT is a significant scientific and technological
breakthrough, which will allow the fabrication of heretofore inaccessible populations of
nanobiomaterials which are poised to revolutionize and accelerate our translational
understanding, detection, and treatment of disease.
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Fig. 1. Illustration of PRINT
Fabrication of the silicon master template (box, upper left); Wetting of the silicon master with
(green) liquid fluoropolymer, followed by curing (top row); PFPE elastomeric mold produced
with nanoscale features from the master (upper right); Confining (red) organic liquid to
cavities by applying pressure between mold and a PFPE surface (middle row); Removal of
organic particles from mold with adhesive layer (bottom left); Dissolution of adhesive layer
producing free particles (bottom right)
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Fig. 2. Results of the PRINT Process
Top row, left to right: A) SEM of an etched silicon wafer master template of 3 μm posts
having a height of 1.7 μm; B) Cured PFPE mold of the master template shown in A; C) PFPE
mold containing PEG particles prior to harvesting; D) Harvested and dispersed PEG PRINT
particles. Bottom row, left to right: E) SEM of an etched silicon wafer patterned with
approximately 400 billion posts that are 100 nm in diameter and 400 nm tall; F) A cured PFPE
mold of the silicon master template shown in E; G) 100 nm PEG particles made using PRINT
and transferred to a medical adhesive layer for surface functionalization and subsequent
harvesting
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Fig. 3. Chemical structures of monomers and a partial structure of the PRINT nanogel
p-Hydroxystyrene was introduced for radioiodination at 1% (w/w). Throughout the present
study, it is assumed that iodinated PRINT nanogels behave the same as unmodified particles.
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Scanning electron micrographs of 200 nm PRINT particles used in the present study
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A time-dependent study of the mean diameter, polydispersity and stability of PRINT particles
(top), and liposomes (bottom) using dynamic light scattering
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MTS assay depicting the non-toxic nature of 200 nm PRINT particles incubated with HeLa
cells. Approximately 103 cells were plated per 1 cm2. Cells were exposed to varying
concentrations of PRINT particles in 0.1 mL media for 4 h at 37 °C before the MTS assay was
performed. Control wells, where the cells were exposed to only PBS serve as 100% in
normalization. Vertical bars stand for one SD with n = 5.
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Biodistribution of 200 nm [125I]-labeled PRINT particles in healthy mice subsequent to bolus
tail vein injection at a dose of 20 mg/kg. The organ accumulation is expressed as a percent of
injected dose after animals were sacrificed at 10 min, 30 min, 1, 3, 8, and 24 h post-intravenous
injection. The organ data is presented as the mean ± SD with n = 4. The recovery found in the
blood assumes a blood volume of 2.18 mL/25 g mouse [34].
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Fig. 8. Blood pharmacokinetic profile of PRINT particles in healthy C57BL/6J mice
At given time intervals, four animals were sacrificed and blood was collected via cardiac
puncture. Radioactivity observed was converted to particle concentration using the specific
radioactivity measured and assuming a total blood volume of 2.18 mL/25 g mouse [34]. The
data was subject to two-compartmental analysis (WinNonlin) resulting in pharmacokinetic
parameters discussed in the text. For simplicity, data obtained 24 h post-injection are not shown
in the figure or used for PK parameter determination.
Gratton et al. Page 19
J Control Release. Author manuscript; available in PMC 2008 August 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
